Skip to main content

Advertisement

Log in

Cryptococcosis in China (1985–2010): Review of Cases from Chinese Database

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

Background

Cryptococcosis is a potential fatal disease, especially in immunocompromised patients. In China, the profile of cryptococcosis is unclear. Therefore, we summarize the epidemiology and therapy of cryptococcosis in china.

Methods

All cases reports about cryptococcosis in China were collected from CBMdisk database (China Biology and Medicine data disc) with key words of cryptococcosis, or cryptococcal infection, or cryptococcus, and case. The features of the cryptococcosis were retrospectively analyzed.

Results

There were 1,032 reports about cryptococcosis, including 8,769 cases. Among them, there were 16% patient with AIDS/HIV, and 17% ones without underlying diseases. There were 2,371 cases of CNS infection. Among them of 2,068 cases, the treatment protocols and outcome were clearly described. The percentages of patients who received intrathecal treatment of amphotericin B(AmB), AmB + 5-FC(5-fluorocytosine), AmB + FCZ(fluconazole), and AmB + 5-FU + FCZ in each medication group were 10, 43, 53, and 33%, respectively. The mortalities were significantly lower in the AmB, Amb + 5-FC, AmB + FCZ intrathecal treatment groups compared with their non-intrathecal treatment controls (6% vs. 23%, 25% vs. 35%, 20% vs. 30%, respectively, P < 0.05), but not in the intrathecal AmB + 5-FU + FCZ group (35% vs. 26%, P > 0.05).

Conclusion

The Chinese cryptococcosis had its own special clinical features, such as more patients without identifiable underlying diseases. Intrathecal injection of amphotericin B was effective treatment method for cryptococcal CNS infection in China.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50:291–322.

    Article  PubMed  Google Scholar 

  2. Subramanian S, Mathai D. Clinical manifestations and management of cryptococcal infection. J Postgrad Med. 2005;51:S21–6.

    PubMed  Google Scholar 

  3. Tay ST, Rohani MY, Soo Hoo TS, et al. Epidemiology of cryptococcosis in Malaysia. Mycoses. 2009;53:509–14.

    Article  Google Scholar 

  4. Tintelnot K, Lemmer K, Losert H, et al. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses. 2004;47:455–64.

    Article  PubMed  CAS  Google Scholar 

  5. Friedman GD, Jeffrey Fessel W, Udaltsova NV, et al. Cryptococcosis: the 1981–2000 epidemic. Mycoses. 2005;48:122–5.

    Article  PubMed  Google Scholar 

  6. Chayakulkeeree M, Perfect JR. Cryptococcosis. In: Duane RH, Michael GR, editors. Diagnosis and treatment of human mycoses. Totowa, New Jersey: Humana Press; 2008. p. 255–77.

    Chapter  Google Scholar 

  7. Wu SX, Guo NR, Li XF, et al. Human pathogenic fungi in China–emerging trends from ongoing national survey for 1986, 1996, and 2006. Mycopathologia. 2011;171:387–93.

    Article  PubMed  CAS  Google Scholar 

  8. Seboxa T, Alemu S, Assefa A, et al. Cryptococcal meningitis in patients with acquired immunodeficiency syndrome in prehaart era at Gondar College of Medical Sciences Hospital north-west Ethiopia. Ethiop Med J. 2010;48:237–41.

    PubMed  Google Scholar 

  9. Bennett JE, Dismukes W, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301:126–31.

    Article  PubMed  CAS  Google Scholar 

  10. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007;5:355–60.

    Article  PubMed  CAS  Google Scholar 

  11. Manosuthi W, Sungkanuparph S, Thongyen S, et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. J Med Assoc Thai. 2006;89:795–802.

    PubMed  Google Scholar 

  12. Tintelnot K, SchaÈr G, Polak A, et al. Epidemiological data of cryptococcosis in Austria, Germany and Switzerland: part of the ECMM survey in Europe. Mycoses. 2001;44:345–50.

    Article  PubMed  CAS  Google Scholar 

  13. Chen J, Wen H, Wu J, et al. Adverse effects of amphotericin B during treatment of cryptococcal meningitis and their management. Acad J Sec Mil Med Univ. 2005;26:456–7.

    CAS  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chen Jianghan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yuchong, C., Fubin, C., Jianghan, C. et al. Cryptococcosis in China (1985–2010): Review of Cases from Chinese Database. Mycopathologia 173, 329–335 (2012). https://doi.org/10.1007/s11046-011-9471-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-011-9471-1

Keywords

Navigation